REGENERON PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
REGENERON PHARMACEUTICALS, INC. (REGN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-09-30 was 998.00K shares, a 54.11% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2018 was 0.00 shares.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2016 was 900.00K shares, a 59.93% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2015 was 2.25M shares, a 23.50% decline from fiscal 2014.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | 0.00 shares 10-K · filed 2019-02-07 | ||||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-02-07 | ||||
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-08 | 0.00 shares 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | 0.00 shares 10-Q · filed 2017-08-03 | 0.00 shares 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-04 | ||||
| 2016-12-31 | 900.00K shares 10-K · filed 2019-02-07 | 936.00K shares 10-K · filed 2017-02-09 | |||
| 2016-09-30 | 998.00K shares 10-Q · filed 2017-11-08 | 1.09M shares 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | 984.00K shares 10-Q · filed 2017-08-03 | 1.13M shares 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | 1.28M shares 10-Q · filed 2017-05-04 | ||||
| 2015-12-31 | 2.25M shares 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | 2.17M shares 10-Q · filed 2016-11-04 | 2.40M shares 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | 2.46M shares 10-Q · filed 2016-08-04 | 2.49M shares 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | 2.51M shares 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | 2.94M shares 10-K · filed 2017-02-09 | ||||
| 2014-09-30 | 2.79M shares 10-Q · filed 2015-11-04 | 2.95M shares 10-Q · filed 2015-11-04 | |||
| 2014-06-30 | 2.88M shares 10-Q · filed 2015-08-04 | 3.02M shares 10-Q · filed 2015-08-04 | |||
| 2014-03-31 | 3.16M shares 10-Q · filed 2015-05-07 | ||||
| 2013-12-31 | 2.71M shares 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | 2.88M shares 10-Q · filed 2014-11-04 | 2.56M shares 10-Q · filed 2014-11-04 | |||
| 2013-06-30 | 2.65M shares 10-Q · filed 2014-08-05 | 2.34M shares 10-Q · filed 2014-08-05 | |||
| 2013-03-31 | 1.89M shares 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | 990.00K shares 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | 1.15M shares 10-Q · filed 2013-11-05 | 652.00K shares 10-Q · filed 2013-11-05 | |||
| 2012-06-30 | 831.00K shares 10-Q · filed 2013-08-06 | 341.00K shares 10-Q · filed 2013-08-06 | |||
| 2011-12-31 | 0.00 shares 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |